Go Pro
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel Free NCEL Stock Alerts

NLS Pharmaceutics (NCEL) Financials

NLS Pharmaceutics logo
$3.81 -0.16 (-4.03%)
As of 07/21/2026 04:00 PM Eastern
Compare
Annual Income Statements for NLS Pharmaceutics

Annual Income Statements for NLS Pharmaceutics

This table shows NLS Pharmaceutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -5.15 -5.45 -2.86 -12 -16 -3.33 -7.20 -8.30
Consolidated Net Income / (Loss)		 -5.15 -5.45 -2.86 -12 -16 -3.33 -7.20 -8.30
Net Income / (Loss) Continuing Operations		 -5.15 -5.45 -2.86 -12 -16 -3.35 -7.20 -7.65
Total Pre-Tax Income 		-5.15 -5.45 -2.86 -12 -16 -3.35 -7.20 -7.65
Total Operating Income		 -3.45 -4.20 -2.30 -12 -15 -3.02 -2.07 -2.56
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 3.45 4.20 2.30 12 15 3.02 2.07 2.56
Selling, General & Admin Expense		 2.74 3.30 2.20 5.94 6.51 1.33 1.07 1.44
Marketing Expense		 - - - - - 0.08 0.00 0.00
Research & Development Expense		 0.71 0.90 0.10 5.92 8.98 1.61 0.99 1.13
Total Other Income / (Expense), net		 -1.70 -1.25 -0.56 -0.07 -0.91 -0.33 -5.13 -5.09
Other Income / (Expense), net		 0.02 -0.07 -0.33 -0.02 0.01 -0.33 -5.13 -5.09
Basic Earnings per Share		 - - ($0.41) ($1.00) ($33.52) $1.13 $2.43 $2.16
Weighted Average Basic Shares Outstanding		 6.24M 6.84M 6.96M 11.90M 492.07K 2.96M 2.96M 3.84M
Diluted Earnings per Share		 - - - - ($33.52) $1.13 $2.43 $2.16
Weighted Average Diluted Shares Outstanding		 6.24M 6.84M 6.96M 11.90M 492.07K 2.96M 2.96M 3.84M
Weighted Average Basic & Diluted Shares Outstanding		 6.24M 6.84M 6.96M 11.90M 32.43M 35.67M 3.16M 4.80M

Quarterly Income Statements for NLS Pharmaceutics

No quarterly income statements for NLS Pharmaceutics are available.

Annual Cash Flow Statements for NLS Pharmaceutics

This table details how cash moves in and out of NLS Pharmaceutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -2.18 0.21 -0.13 5.34 3.52 -0.60 0.37 1.55
Net Cash From Operating Activities		 -2.73 -0.19 -0.73 -15 -14 -3.44 -1.07 -2.77
Net Cash From Continuing Operating Activities		 -2.73 -0.19 -0.73 -15 -14 -3.56 -0.07 -2.73
Net Income / (Loss) Continuing Operations		 -5.15 -5.45 -2.86 -12 -16 -3.33 -7.20 -8.30
Consolidated Net Income / (Loss)		 -5.15 -5.45 -2.86 -12 -16 -3.33 -7.20 -8.30
Depreciation Expense		 - 0.00 0.00 0.01 0.01 0.62 0.41 0.06
Non-Cash Adjustments To Reconcile Net Income		 0.66 0.39 0.02 0.12 0.91 0.69 5.24 7.37
Changes in Operating Assets and Liabilities, net		 0.67 4.12 2.04 -3.17 1.63 -1.53 1.47 -1.85
Net Cash From Investing Activities		 0.00 0.00 0.00 -0.04 0.00 0.10 -0.01 1.70
Net Cash From Continuing Investing Activities		 0.00 0.00 0.00 -0.04 0.00 0.10 -0.01 1.70
Purchase of Property, Plant & Equipment		 - 0.00 0.00 -0.04 0.00 -0.01 -0.01 -0.01
Acquisitions		 - - - - - 0.00 0.00 1.71
Sale of Property, Plant & Equipment		 - - - - - 0.11 0.00 0.00
Net Cash From Financing Activities		 0.56 0.41 0.50 20 17 2.85 0.45 2.63
Net Cash From Continuing Financing Activities		 0.56 0.41 0.50 20 17 2.85 0.45 2.63
Issuance of Debt		 0.56 0.67 0.36 0.11 1.53 1.24 0.45 0.29
Issuance of Common Equity		 - 0.00 0.00 21 16 1.61 0.00 0.00
Other Financing Activities, net		 0.00 0.00 0.83 1.15 0.02 0.00 0.00 2.34
Effect of Exchange Rate Changes		 -0.00 -0.00 - -0.02 - - - -0.01
Cash Interest Paid		 - 0.00 0.00 0.34 0.01 0.09 0.13 0.02
Cash Income Taxes Paid		 - - - - - 0.00 0.00 0.00

Quarterly Cash Flow Statements for NLS Pharmaceutics

No quarterly cash flow statements for NLS Pharmaceutics are available.

Annual Balance Sheets for NLS Pharmaceutics

This table presents NLS Pharmaceutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 0.70 1.21 5.76 9.28 1.85 0.90 11
Total Current Assets		 0.38 0.20 5.72 9.25 1.82 0.78 3.18
Cash & Equivalents		 0.22 0.09 5.43 8.95 0.90 0.65 2.20
Prepaid Expenses		 0.16 0.10 0.29 0.30 0.93 0.13 0.98
Plant, Property, & Equipment, net		 0.00 0.00 0.03 0.02 0.01 0.12 0.10
Total Noncurrent Assets		 0.31 1.01 0.01 0.01 0.02 0.00 8.17
Goodwill		 - - - - - 0.00 1.73
Intangible Assets		 - - - - - 0.00 6.44
Total Liabilities & Shareholders' Equity		 0.70 1.21 5.76 9.28 1.85 0.90 11
Total Liabilities		 6.87 10 5.22 6.00 11 8.90 4.20
Total Current Liabilities		 4.04 7.20 2.40 3.36 7.92 8.90 4.20
Short-Term Debt		 0.69 1.21 - 0.00 1.63 1.81 0.36
Accounts Payable		 2.61 4.47 1.74 2.37 4.63 1.17 2.17
Other Current Liabilities		 0.00 0.57 - - - 5.92 0.00
Total Noncurrent Liabilities		 2.83 2.99 2.82 2.64 2.76 0.00 1.67
Noncurrent Deferred & Payable Income Tax Liabilities		 - - - - - 0.00 1.67
Total Equity & Noncontrolling Interests		 -6.17 -8.98 0.54 3.28 -8.83 -8.00 7.25
Total Preferred & Common Equity		 -6.17 -8.98 0.54 3.28 -8.83 -8.00 7.25
Preferred Stock		 - - - - 0.00 0.00 0.00
Total Common Equity		 -6.17 -8.98 0.54 3.28 -8.83 -8.00 7.25
Common Stock		 21 21 42 62 62 70 94
Retained Earnings		 -27 -30 -42 -58 -70 -77 -85
Accumulated Other Comprehensive Income / (Loss)		 -0.02 -0.02 -0.15 -0.05 -0.16 -1.09 -1.85

Quarterly Balance Sheets for NLS Pharmaceutics

No quarterly balance sheets for NLS Pharmaceutics are available.

Annual Metrics And Ratios for NLS Pharmaceutics

This table displays calculated financial ratios and metrics derived from NLS Pharmaceutics' official financial filings.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 0.00 6,960,000.00 16,223,389.00 32,428,893.00 35,671,780.00 35,671,780.00 35,671,780.00
DEI Adjusted Shares Outstanding		 0.00 0.00 17,400.00 40,558.00 81,072.00 89,179.00 89,179.00 89,179.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 -164.45 -294.54 -203.47 -37.36 -80.70 -93.07
Growth Metrics		 - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -49.71% 27.13% -362.77% -30.17% 82.28% -148.72% -11.91%
EBIT Growth		 0.00% -24.17% 38.35% -352.02% -30.26% 78.36% -114.99% -6.25%
NOPAT Growth		 0.00% -21.69% 45.21% -415.82% -30.54% 80.53% 31.48% -24.01%
Net Income Growth		 0.00% -5.84% 47.47% -317.49% -38.08% 79.80% -116.00% -15.33%
EPS Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 79.80% 115.04% -11.11%
Operating Cash Flow Growth		 0.00% 93.05% -283.87% -1,947.76% 7.07% 75.19% 69.05% -159.47%
Free Cash Flow Firm Growth		 0.00% 0.00% -89.59% -4,294.24% 5.60% 103.18% -946.08% -419.42%
Invested Capital Growth		 0.00% 0.00% -34.65% 32.50% -15.93% -42.87% 15.52% 178.99%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profitability Metrics		 - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.17% 100.62% 99.52% 99.99% 108.53%
Interest Burden Percent		 149.93% 127.79% 108.89% 100.41% 105.96% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 0.00% 88.27% 37.76% 283.03% -862.92% 120.01% 85.53% 2,225.20%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -259.78%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 0.00% 88.27% 37.76% 283.03% -862.92% 120.01% 85.53% 2,237.13%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 88.27% 31.85% -2,202.50% -502.79% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -2.41 -2.94 -1.61 -8.30 -11 -2.11 -1.45 -1.79
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 0.00% 633.54% 98.82% -197.51% -78.70% -29.75% 608.21% -1,883.24%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - -330.33% 29.31% 23.36% -23.58%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -3.43 -4.26 -2.63 -12 -15 -3.35 -7.20 -7.65
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -2.34 -3.51 -2.56 -12 -15 -2.73 -6.79 -7.59
Valuation Ratios		 - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 14.24 6.38 0.00 0.00 0.02
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 14.24 6.38 0.00 0.00 0.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 6.44 65.01 0.00 0.00 62.19 0.00 0.00
Leverage & Solvency		 - - - - - - - -
Debt to Equity		 0.00 -0.14 -0.17 0.00 0.00 -0.18 -0.23 0.05
Long-Term Debt to Equity		 0.00 -0.02 -0.03 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 0.00 -0.13 -0.17 0.44 -3.76 1.48 -0.11 0.93
Leverage Ratio		 0.00 -0.11 -0.13 -0.83 3.93 -2.00 -0.16 -16.55
Compound Leverage Factor		 0.00 -0.14 -0.14 -0.83 4.17 -2.00 -0.16 -16.55
Debt to Total Capital		 0.00% -15.80% -20.35% 0.00% 0.00% -22.69% -29.16% 4.67%
Short-Term Debt to Total Capital		 0.00% -12.95% -16.15% 0.00% 0.00% -22.69% -29.16% 4.67%
Long-Term Debt to Total Capital		 0.00% -2.85% -4.20% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.05%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% 115.80% 120.35% 100.00% 100.00% 122.69% 129.16% 95.28%
Debt to EBITDA		 0.00 -0.24 -0.59 0.00 0.00 -0.60 -0.27 -0.05
Net Debt to EBITDA		 0.00 -0.18 -0.56 0.00 0.00 -0.27 -0.17 0.24
Long-Term Debt to EBITDA		 0.00 -0.04 -0.12 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 -0.29 -0.94 0.00 0.00 -0.77 -1.25 -0.20
Net Debt to NOPAT		 0.00 -0.21 -0.89 0.00 0.00 -0.35 -0.80 1.03
Long-Term Debt to NOPAT		 0.00 -0.05 -0.19 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 -79.25 -47.60 -15.35 -11.43 -62.22 -155.71 -12.67
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -0.54%
Liquidity Ratios		 - - - - - - - -
Current Ratio		 0.00 0.09 0.03 2.38 2.75 0.23 0.09 0.76
Quick Ratio		 0.00 0.05 0.01 2.26 2.66 0.11 0.07 0.52
Cash Flow Metrics		 - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 2.44 0.25 -11 -10 0.32 -2.70 -14
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% -37,755.42% 0.00% 0.00% -17,766.67% -34,575.00%
Free Cash Flow to Firm to Interest Expense		 0.00 2.06 1.09 -221.54 -10.90 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 -1.59 -0.16 -3.12 -310.52 -15.05 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -1.59 -0.16 -3.12 -311.34 -15.05 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - -
Invested Capital		 0.00 -5.38 -7.24 -4.89 -5.67 -8.10 -6.84 5.40
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 -5.38 -1.86 2.35 -0.78 -2.43 1.26 12
Enterprise Value (EV)		 0.00 16 17 2.29 12 20 3.04 -1.67
Market Capitalization		 15 15 15 7.73 21 19 1.88 0.17
Book Value per Share		 $0.00 ($0.90) ($1.29) $0.08 $0.20 ($0.27) ($0.22) $1.89
Tangible Book Value per Share		 $0.00 ($0.90) ($1.29) $0.08 $0.20 ($0.27) ($0.22) ($0.24)
Total Capital		 0.00 -5.33 -7.46 0.54 3.28 -7.20 -6.19 7.61
Total Debt		 0.00 0.84 1.52 0.00 0.00 1.63 1.81 0.36
Total Long-Term Debt		 0.00 0.15 0.31 0.00 0.00 0.00 0.00 0.00
Net Debt		 0.00 0.62 1.43 -5.43 -8.95 0.74 1.16 -1.85
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.04 0.00 -0.10 0.01 0.01
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -3.18 -5.90 -2.11 -3.06 -5.36 -6.96 -2.86
Debt-free Net Working Capital (DFNWC)		 0.00 -2.96 -5.80 3.32 5.89 -4.46 -6.31 -0.66
Net Working Capital (NWC)		 0.00 -3.65 -7.01 3.32 5.89 -6.10 -8.12 -1.01
Net Nonoperating Expense (NNE)		 2.73 2.51 1.25 3.64 5.66 1.22 5.75 6.51
Net Nonoperating Obligations (NNO)		 0.00 0.79 1.74 -5.43 -8.95 0.74 1.16 -1.85
Total Depreciation and Amortization (D&A)		 1.09 0.76 0.07 0.05 0.08 0.62 0.41 0.06
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 $0.00 ($33.60) ($128.00) ($26.30) $2.16
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 6.96M 16.22M 492.07K 95.44K 154.33K 3.84M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 ($26.30) $2.16
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 6.96M 16.22M 810.72K 89.18K 154.33K 3.84M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 6.96M 11.90M 810.72K 89.18K 315.95K 4.80M
Normalized Net Operating Profit after Tax (NOPAT)		 -2.41 -2.94 -1.61 -8.30 -11 -2.11 -1.45 -1.79
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - -
EBIT to Interest Expense		 -2.00 -3.60 -11.24 -246.94 -16.77 0.00 0.00 0.00
NOPAT to Interest Expense		 -1.41 -2.48 -6.89 -172.61 -11.75 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 -2.00 -3.60 -11.24 -247.77 -16.77 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -1.41 -2.48 -6.89 -173.43 -11.75 0.00 0.00 0.00
Payout Ratios		 - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for NLS Pharmaceutics

No quarterly metrics and ratios for NLS Pharmaceutics are available.


Financials Breakdown Chart

NLS Pharmaceutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, NLS Pharmaceutics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

NLS Pharmaceutics' net income appears to be on an upward trend, with a most recent value of -$8.30 million in 2025, rising from -$5.15 million in 2018. The previous period was -$7.20 million in 2024. View NLS Pharmaceutics' forecast to see where analysts expect NLS Pharmaceutics to go next.

NLS Pharmaceutics' total operating income in 2025 was -$2.56 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $2.56 million

Over the last 7 years, NLS Pharmaceutics' total revenue changed from $0.00 in 2018 to $0.00 in 2025, a change of 0.0%.

NLS Pharmaceutics' total liabilities were at $4.20 million at the end of 2025, a 52.9% decrease from 2024, and a 38.9% decrease since 2019.

In the past 6 years, NLS Pharmaceutics' cash and equivalents has ranged from $93.71 thousand in 2020 to $8.95 million in 2022, and is currently $2.20 million as of their latest financial filing in 2025.

Over the last 7 years, NLS Pharmaceutics' book value per share changed from 0.00 in 2018 to 1.89 in 2025, a change of 188.5%.


Related Companies

Financial statements for NASDAQ:NCEL last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
The options guide that actually starts at the beginning
Most options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...
Base Camp Trading | Sponsoredtc pixel
BlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
Elon says “don’t save money.” Is he right?
Robert Kiyosaki, author of Rich Dad Poor Dad, says you don't have to wait for Elon Musk's vision of universal ...
Freedom Financial | Sponsoredtc pixel
Oxford Club Analyst’s Urgent AI Warning
Alexander Green, Chief Investment Strategist at The Oxford Club, is sharing a private presentation with a warn...
The Oxford Club | Sponsoredtc pixel
The Starlink of Energy
A portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...
Monument Traders Alliance | Sponsoredtc pixel
30-Year market veteran reveals America’s #1 Stock
Market veteran Jim Woods has flagged triple-digit gains multiple times in under two months - 151% on Netflix, ...
Eagle Publishing | Sponsoredtc pixel
Man who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”
In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...
Paradigm Press | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel